Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Papillomavirus Infections · Coronavirus Disease (COVID-19)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 165 (final count)
- Started
- Mar 28, 2022
- Main results expected
- Dec 12, 2023
- Fully finished
- Dec 12, 2023
- Results posted
- Jul 17, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Geometric Mean Titers of Anti-Human Papillomavirus Vaccine Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (9vHPV)
Measured over: Up approximately 4 weeks post vaccination with 9vHPV Dose 2
Geometric Mean Concentrations of SARS-CoV-2 Spike Protein-Specific Binding Antibodies
Measured over: Up approximately 4 weeks post vaccination with mRNA-1273 Dose 2
Percentage of Participants With ≥1 Solicited Injection-site Adverse Event (AE)
Measured over: Up to approximately Day 7 post vaccination with any study vaccine
Percentage of Participants With ≥1 Solicited Systemic AE
Measured over: Up to approximately Day 7 post vaccination with any study vaccine
Percentage of Participants With ≥1 Serious Adverse Event (SAE)
Measured over: Up to approximately Day 28 post vaccination with any study vaccine
Percentage of Participants With ≥1 Vaccine-Related SAE
Measured over: Up to approximately 9 Months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05119855 · record last updated 2026-02-05 · checked 2026-11-09 15:47 UTC